Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association

Mehta, Anurag; Sriramanakoppa, Nayana N; Agarwal, Poojan; Viswakarma, Gayatri; Vasudevan, Smreti; Panigrahi, Manoj Kumar; Kumar, Dushyant; Saifi, Mumtaz; Chowdhary, Irfan; Doval, DC; Suryavanshi, Moushumi

doi:10.4103/sajc.sajc_373_18

Cited by 5 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding tumor genomic alterations, the EGFR mutations were detected in 23.3% of the patients, and as expected, they were more prevalent in non-smokers than in smokers. These findings are analogous to previously published reports from Asia that report a higher frequency of EGFR mutations in Asian cohorts [ 18 , 25 , 28 ].…”

Section: Discussionsupporting

confidence: 92%

Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers

Vasudevan¹,

Krishna²,

Mehta³

2022

Cureus

Self Cite

View full text Add to dashboard Cite

BackgroundLung cancer in non-smokers is a clinically distinct entity based on unique epidemiology, clinicopathology, genetics, treatment response, and outcome. Data from Indian centres are scarce. The objective of this study was to compare the frequency, clinical characteristics, driver mutations, and survival of non-smoking and smoking lung cancer patients treated at a tertiary cancer centre in North India. MethodologyTwo years of data on 724 consecutive lung cancer patients were assessed. Clinical, demographics, smoking history, and EGFR and ALK mutation test results were collected. Descriptive and inferential statistics were applied. Survival analysis was performed using the Kaplan-Meier method. ResultsNon-smokers comprised 40.9% of the study sample. Non-smokers were more likely than smokers to experience disease onset at a younger age (P = 0.004) and metastasis (P < 0.001). The tumor histology showed significant differences (P < 0.001), with non-smokers more likely to be diagnosed with adenocarcinoma (77.4%), while squamous and small cell histologies were commonly found among smokers (37.6% and 13.8%, respectively). The EGFR mutation and ALK rearrangement rates in the cohort were 23.3% and 10.1%, respectively, and were more frequent in non-smoking patients. Overall, 10-year survival was 7%, with a significantly better survival rate of non-smokers than smokers (median survival time of 15.13 vs 10.17 months; P = 0.012). ConclusionsAbout four out of 10 patients diagnosed with lung cancer at our centre were non-smokers. They were more often young, diagnosed at an advanced stage, with predominantly adenocarcinoma histology, and had a threefold higher frequency of EGFR mutations than smokers. In our cohort, non-smokers appear to be a targetable group with better survival than smokers.

show abstract

Section: Discussionsupporting

confidence: 92%

Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers

Vasudevan¹,

Krishna²,

Mehta³

2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been shown that multiple genes can be used as potential biomarkers for the diagnosis and prognosis of lung cancer ( 54 , 55 ). However, to the best of our knowledge, there are currently limited studies available on the effective molecular diagnostic markers of LUAD and LUSC.…”

Section: Discussionmentioning

confidence: 99%

Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma

Cao

Wang

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

The determination of biomarkers in the blood specific for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is crucial for the selection of effective treatment strategies and the prediction of prognosis. The purpose of the present study was to analyze the differentially expressed genes (DEGs) in LUSC and LUAD from The Cancer Genome Atlas (TCGA) database. In order to identify the potential biomarkers for non-small cell lung cancer (NSCLC) for clinical diagnosis, bioinformatics was used to analyze the DEGs of two subtypes of NSCLC, LUAD and LUSC. Exosomes were isolated from the serum of patients with LUAD or LUSC and identified using transmission electron microscopy, nanoparticle tracking analysis and western blot analysis. A total of four differential exosomal mRNAs were selected for validation with serum samples from 70 patients with NSCLC via reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were established to evaluate the clinical diagnostic value of four DEGs for patients with LUAD and LUSC. The analysis based on TCGA data revealed the DEGs in LUSC and LUAD: A total of 1,619 genes were differentially expressed in patients with LUSC and LUAD. DEGs analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed that inflammation-related signaling pathways, such as complement pathways, and multiple autoimmune diseases, such as systemic lupus erythematosus and asthma were mainly enriched in LUAD. The cell cycle, Hippo signaling pathway, Rap1 signaling pathway and Wnt signaling pathway were the main signaling pathways enriched in LUSC. The combination of tumor protein P63 (TP63), keratin 5 (KRT5), CEA cell adhesion molecule 6 (CEACAM6) and surfactant protein B (SFTPB) improved the specificity and sensitivity in the diagnosis of different lung cancer subtypes. Exosomal TP63, KRT5, CEACAM6 and SFTPB mRNAs can thus be used as biomarkers to differentiate between LUSC and LUAD, and may provide a novel strategy for their differential diagnosis and treatment.

show abstract

Clinical Characteristics and Treatment Outcomes of Patients with Ovarian Germ Cell Tumor Treated at a Tertiary Care Center in Patna, India

Singh

Anant

et al. 2020

Indian J Gynecol Oncolog

View full text Add to dashboard Cite

Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association

Cited by 5 publications

References 21 publications

Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers

Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers

Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma

Clinical Characteristics and Treatment Outcomes of Patients with Ovarian Germ Cell Tumor Treated at a Tertiary Care Center in Patna, India

Contact Info

Product

Resources

About